A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.
Also called NCT06755944
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 360 participants
- Registry
-
NCT06755944
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06755944. Randomized; quadruple masking; primary purpose treatment. Start 2024-12-15 (actual); primary completion 2025-06-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase Ⅱb Study of XY03-EA Tablets in Acute Ischemic Stroke
- Acronym
- XY03-EA
- Condition
- Stroke, Ischemic
- Intervention (Drug)
- XY03-EA 150 mg (per dose)
- Intervention (Drug)
- XY03-EA 300 mg (Regimen A)
- Intervention (Drug)
- XY03-EA 300 mg (Regimen B)
- Intervention (Drug)
- XY03-EA 450 mg (per dose)
- Intervention (Drug)
- Matching Placebo
- Lead sponsor
- Shijiazhuang Yiling Pharmaceutical Co. Ltd
Record details
- Record id
cardio:ct-nct06755944- Content hash
567d2e0820076d32a62508418e234e4e60906da00ff4c8a937ade0b66458d800